The primary biliary cholangitis (PBC) treatment market — therapies for a chronic autoimmune cholestatic liver disease characterized by progressive destruction of small and medium-sized intrahepatic bile ducts — has experienced one of the most consequential shakeups in its treatment history within just the past year, with the Primary Biliary Cholangitis Treatment Market reflected across analyst estimates that vary by scope, generally sizing the market at approximately USD 1.33 billion in 2024 with projections pointing toward figures between USD 2.72 billion and USD 5.5 billion by the early-to-mid 2030s, at compound annual growth rates ranging from roughly 7.8% up to as high as 21.3% for broader therapeutics-market definitions. The single most consequential recent development reshaping the entire competitive landscape was Intercept Pharmaceuticals' voluntary withdrawal of Ocaliva (obeticholic acid) from the U.S. market in September 2025 — Ocaliva had been the first FDA-approved second-line therapy for PBC patients with inadequate response to first-line treatment, but its withdrawal, alongside U.S. clinical trials involving obeticholic acid being placed on clinical hold, reflects evolving safety considerations that had already made the drug's use increasingly selective even before the formal withdrawal, and has left a meaningful gap in the second-line treatment landscape that competing newer therapies are now positioned to fill. Ursodeoxycholic acid (UDCA) remains the unambiguous first-line standard of care, though a substantial minority of patients don't respond adequately — UDCA, a secondary bile acid produced by intestinal bacteria, has been the cornerstone first-line PBC treatment for many years given its well-established safety profile, but approximately 30-40% of patients have an inadequate biochemical response to UDCA alone, creating a persistent and clinically significant treatment gap that has directly driven demand for effective second-line options. Two newly approved PPAR agonists have rapidly filled the second-line vacuum left by Ocaliva's withdrawal — elafibranor (Iqirvo), which surpassed $200 million in sales during its first full year on the market according to recent reporting, and seladelpar (Livdelzi), which received FDA accelerated approval in August 2024 and is now projected by some analysts to eventually overtake UDCA as the single largest revenue-generating PBC treatment segment, have both demonstrated favorable biochemical efficacy, safety, and tolerability, particularly regarding improvement of the severe itching (pruritus) that significantly affects PBC patients' quality of life. Fenofibrate represents an important, if officially unapproved, practical treatment option that continues seeing real-world clinical use — this PPAR-alpha agonist has shown substantial alkaline phosphatase reductions when added to UDCA therapy in patients with inadequate response, and despite remaining off-label and lacking large-scale confirmatory trial data (unlike the newer FDA-approved agents), it continues to be used as a practical and accessible adjunct treatment given its low cost and long track record in other conditions. The pipeline continues actively expanding beyond currently approved options — linerixibat (Lynavoy), an ileal bile acid transporter inhibitor, has been approved specifically for cholestatic pruritus in PBC patients, reflecting how newer drug development in this space is increasingly targeting specific debilitating symptoms like itching, not just the underlying biochemical markers of disease progression, broadening the overall PBC treatment toolkit well beyond the traditional UDCA-and-second-line-agent framework.

Do you think seladelpar and elafibranor will successfully and durably fill the treatment gap left by Ocaliva's withdrawal, or will ongoing questions about long-term outcomes data for these newer PPAR agonists (given their comparatively short track record) create renewed uncertainty in second-line PBC treatment selection over the coming years?

FAQ

Why was Ocaliva (obeticholic acid) withdrawn from the U.S. market, and what does this mean for PBC patients? Intercept Pharmaceuticals voluntarily withdrew Ocaliva (obeticholic acid) from the U.S. market for primary biliary cholangitis in September 2025, with U.S. clinical trials involving obeticholic acid also placed on clinical hold, reflecting evolving safety considerations regarding the drug that had already made its clinical use increasingly selective even prior to the formal withdrawal. Ocaliva had been the first FDA-approved second-line therapy for PBC patients with an inadequate response to first-line ursodeoxycholic acid (UDCA) treatment, a role it had held for a significant portion of its market history. Its withdrawal has created a meaningful gap in the second-line PBC treatment landscape, though this gap is being actively filled by two more recently approved alternatives — elafibranor (Iqirvo) and seladelpar (Livdelzi) — both peroxisome proliferator-activated receptor (PPAR) agonists that have demonstrated favorable efficacy and tolerability profiles in clinical use, positioning them as the current standard second-line options for patients who don't respond adequately to UDCA alone.

What is the current standard treatment approach for primary biliary cholangitis, and what treatment gap remains? Ursodeoxycholic acid (UDCA) remains the universally recommended first-line therapy for PBC, valued for its well-established long-term safety profile and effectiveness in slowing disease progression and improving liver function markers for the majority of patients. However, an estimated 30-40% of patients have an inadequate biochemical response to UDCA alone, meaning their disease continues to progress despite first-line treatment — this substantial treatment gap has historically been addressed through second-line therapy, a category that has undergone significant recent change following Ocaliva's 2025 market withdrawal. Currently, elafibranor and seladelpar serve as the primary FDA-approved second-line options for UDCA-inadequate responders, while fenofibrate, though not officially FDA-approved for PBC, continues to see real-world off-label use as a practical, accessible adjunct treatment given its demonstrated ability to meaningfully reduce alkaline phosphatase levels when added to UDCA therapy.

#PrimaryBiliaryCholangitis #PBC #LiverDisease #Ocaliva #Seladelpar #Elafibranor #AutoimmuneLiverDisease